Kronos Bio, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 10 rows in 2020. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-12-10: Reporting owner BISCHOFBERGER NORBERT W; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-12-09: Reporting owner Kosacz Barbara; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-12-09: Reporting owner Dinsmore Christopher; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-12-09: Reporting owner DiMartino Jorge; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-12-10 | BISCHOFBERGER NORBERT W Director, Officer (President & CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +297,186 297,186 owned after | $30.78 exercise price | 2020-12-11 | |
| 2020-12-09 | Kosacz Barbara Officer (COO & General Counsel) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +104,736 104,736 owned after | $30.94 exercise price | 2020-12-11 | |
| 2020-12-09 | Dinsmore Christopher Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +136,665 136,665 owned after | $30.94 exercise price | 2020-12-11 | |
| 2020-12-09 | DiMartino Jorge Officer (Chief Medical Officer & VP) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,906 200,906 owned after | $30.94 exercise price | 2020-12-11 | |
| 2020-12-09 | Al-Wakeel Yasir B. Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +108,633 108,633 owned after | $30.94 exercise price | 2020-12-11 | |
| 2020-10-08 holding as of filing | Ridloff Elena Director | 3 | Director Stock Option (Right to Buy) Derivative · Direct | Holding | $13.35 exercise price | 2020-10-08 | ||
| 2020-10-08 holding as of filing | TANEN DAVID M Director | 3 | Employee Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $4.14 exercise price | 2020-10-08 | ||
| 2020-10-08 holding as of filing | Dinsmore Christopher Officer (Chief Scientific Officer) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $3.27 exercise price | 2020-10-08 | ||
| 2020-10-08 holding as of filing | DiMartino Jorge Officer (Chief Medical Officer & VP) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $2.53 exercise price | 2020-10-08 | ||
| 2020-10-08 holding as of filing | Al-Wakeel Yasir B. Officer (Chief Financial Officer) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $7.51 exercise price | 2020-10-08 |